Tc-99m Tetrofosmin - GE Healthcare

Drug Profile

Tc-99m Tetrofosmin - GE Healthcare

Alternative Names: Myoview; MYOVIEW 30mL; MYOVIEW24; PPN-1011; Tc-99m tetrofosmin SPECT; Tc-99m-PPN1011; Technetium (99MTC) Tetrofosmin; Technetium-Tm99m-tetrofosmin

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amersham
  • Developer Amersham; GE Healthcare
  • Class Heavy metals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Coronary disorders; Ischaemia
  • Phase II Brain cancer

Most Recent Events

  • 07 Jun 2016 Chemical information added
  • 26 Apr 2016 Phase II clinical trials in Brain cancer (Diagnosis, In adults, In the elderly) in Germany (IV) (EudraCT2015-005573-21)
  • 23 Nov 2001 Registered for Coronary disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top